THE Department of Health, Disability and Ageing has advised that the chapter on respiratory syncytial virus (RSV) in the Australian Immunisation Handbook has been updated.
Changes relate to the age extension of Arexvy, with a conditional recommendation for eligible adults aged 50-59; clinical guidance on managing administration errors; and incorporation of updated advice on the post-vaccination risk of Guillain-Barre syndrome for Abryso and Arexvy.
Learn more about RSV and other updates HERE.
Meanwhile, changes to the NIP childhood pneumococcal vaccination schedule will take effect from 01 Sep, including the introduction of Prevenar 20 to replace Prevenar 13 and Pneumovax 23.
Prevenar 20 covers more strains of the disease and requires fewer doses.
There will also be changes to the dosing regimen.
The above article was sent to subscribers in Pharmacy Daily's issue from 08 Aug 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 08 Aug 25
